BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines global Full-Time Employees (Form 10-K / 10-Q & ESG Report)
Form 10-K / 10-Q & BeOne Responsible Business & Sustainability Reports (2019–2025)
Latest, Q2 2026
12,000
Period ended Jun 30, 2026
Change on a year earlier
+9.1%
11,000 in Q2 2025
History
21 quarters
Since Q4 2020
Sources
21
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Global Full-Time Employees (Form 10-K / 10-Q & ESG Report) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 12,000 | +9.1% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 12,000 | +9.1% | Form 10-Q (filed 2026-05-06) ↗ |
| Q4 2025 | Dec 31, 2025 | 12,000 | +9.1% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2025 | Sep 30, 2025 | 12,000 | – | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 11,000 | – | Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2025 | Mar 31, 2025 | 11,000 | +10.0% | Form 10-Q (filed 2025-05-07) ↗ |
| Q4 2024 | Dec 31, 2024 | 11,000 | +10.0% | Form 10-K (filed 2025-02-27) ↗ |
| Q1 2024 | Mar 31, 2024 | 10,000 | +6.4% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 10,000 | +11.1% | Form 10-K (filed 2024-02-26) ↗ |
| Q3 2023 | Sep 30, 2023 | 10,000 | +11.1% | Form 10-Q (filed 2023-11-09) ↗ |
| Q2 2023 | Jun 30, 2023 | 10,000 | +16.3% | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2023 | Mar 31, 2023 | 9,400 | +13.3% | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2022 | Dec 31, 2022 | 9,000 | +12.5% | Form 10-K (filed 2023-02-27) ↗ |
| Q3 2022 | Sep 30, 2022 | 9,000 | +18.4% | Form 10-Q (filed 2022-11-09) ↗ |
| Q2 2022 | Jun 30, 2022 | 8,600 | +34.4% | Form 10-Q (filed 2022-08-08) ↗ |
| Q1 2022 | Mar 31, 2022 | 8,300 | +38.3% | Form 10-Q (filed 2022-05-09) ↗ |
| Q4 2021 | Dec 31, 2021 | 8,000 | +50.9% | Form 10-K (filed 2022-02-28) ↗ |
| Q3 2021 | Sep 30, 2021 | 7,600 | – | Form 10-Q (filed 2021-11-04) ↗ |
| Q2 2021 | Jun 30, 2021 | 6,400 | – | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 6,000 | – | Form 10-Q (filed 2021-05-06) ↗ |
| Q4 2020 | Dec 31, 2020 | 5,300 | – | Form 10-K (filed 2021-02-25) ↗ |
Breakdown
What makes up global full-time employees (form 10-k / 10-q & esg report)
- Approximate U.S. Employees (Form 10-K Human Capital)–
- Full-Time Employees (ESG Performance Table)–
- Part-Time Employees (ESG Performance Table)–
- Contingent Workers (ESG Performance Table)–
- Employees — Asia-Pacific (JAPAC, incl. China)–
- Employees — North America (U.S. & Canada)–
- Employees — Europe–
- Employees — Latin America–
- Employees — Middle East & Africa–
- New Employee Hires During Year (employees)–
- Total Employee Turnover Rate (%)–
- Voluntary Employee Turnover Rate (%)–
- Total Recordable Incident Rate — Employees (TRIR per 100 FTE)–
- Lost-Time Injury Rate — Employees (LTIR per 100 FTE)–
Cite this data
StockData. (2026). BeOne Medicines Global Full-Time Employees (Form 10-K / 10-Q & ESG Report), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/emp_total
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.